✦ LIBER ✦

Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease

✍ Scribed by Henry Sershen; Audrey Hashim; Abel Lajtha

Book ID: 113221227
Publisher: Elsevier Science
Year: 1987
Tongue: English
Weight: 446 KB
Volume: 28
Category: Article
ISSN: 0091-3057
DOI: 10.1016/0091-3057(87)90228-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Biochemical, behavioral and immunohistoc

Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease

✍ Rumiko Kurosaki; Yasuko Muramatsu; Hiroyuki Kato; Tsutomu Araki 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 494 KB

Behavioral phenotyping of the MPTP mouse

Behavioral phenotyping of the MPTP mouse model of Parkinson's disease

✍ Marco Sedelis; Rainer K.W Schwarting; Joseph P Huston 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Preventive effect of antioxidants in MPT

Preventive effect of antioxidants in MPTP-induced mouse model of Parkinson's disease

✍ Soon-Won Park; Sun-Hee Kim; Kyu-Hyun Park; Sang-Doo Kim; Joo-Young Kim; Sun-Yong 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 268 KB

Biochemical alterations of the striatum

Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson’s disease

✍ Hayato Kuroiwa; Hironori Yokoyama; Hiroki Kimoto; Hiroyuki Kato; Tsutomu Araki 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 168 KB

Neuroprotective effects of echinacoside

Neuroprotective effects of echinacoside in the mouse MPTP model of Parkinson's disease

✍ Xingchao Geng; Xuefei Tian; Pengfei Tu; Xiaoping Pu 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 626 KB

Neuroprotective effects of (±)-kavain in

Neuroprotective effects of (±)-kavain in the MPTP mouse model of Parkinson's disease

✍ Nicole Schmidt; Boris Ferger 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 319 KB 👁 2 views

This is the first study to investigate the potential protective effects of the lipophilic kavapyrone (+/-)-kavain in the experimental MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model of Parkinson's disease (PD). Male C57BL/6 mice were treated with (+/-)-kavain (50, 100, or 200 mg/kg i.p.) o